Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally.
Mediocre balance sheet and overvalued.
Share Price & News
How has Endologix's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ELGX's share price has been volatile over the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: ELGX underperformed the US Medical Equipment industry which returned -7.7% over the past year.
Return vs Market: ELGX underperformed the US Market which returned -15.9% over the past year.
Price Volatility Vs. Market
How volatile is Endologix's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StEndologix, Inc. Just Reported, And Analysts Assigned A US$3.80 Price Target
2 months ago | Simply Wall StAre Insiders Buying Endologix, Inc. (NASDAQ:ELGX) Stock?
3 months ago | Simply Wall StWhat Kind Of Shareholder Appears On The Endologix, Inc.'s (NASDAQ:ELGX) Shareholder Register?
Is Endologix undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ELGX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ELGX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ELGX is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: ELGX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ELGX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ELGX is good value based on its PB Ratio (0.2x) compared to the US Medical Equipment industry average (2.9x).
How is Endologix forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ELGX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ELGX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ELGX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ELGX's revenue (6.5% per year) is forecast to grow slower than the US market (7% per year).
High Growth Revenue: ELGX's revenue (6.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ELGX is forecast to be unprofitable in 3 years.
How has Endologix performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ELGX is currently unprofitable.
Growing Profit Margin: ELGX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ELGX is unprofitable, and losses have increased over the past 5 years at a rate of -2.9% per year.
Accelerating Growth: Unable to compare ELGX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ELGX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1%).
Return on Equity
High ROE: ELGX has a negative Return on Equity (-101.41%), as it is currently unprofitable.
How is Endologix's financial position?
Financial Position Analysis
Short Term Liabilities: ELGX's short term assets ($93.7M) exceed its short term liabilities ($55.8M).
Long Term Liabilities: ELGX's short term assets ($93.7M) do not cover its long term liabilities ($187.5M).
Debt to Equity History and Analysis
Debt Level: ELGX's debt to equity ratio (286.1%) is considered high.
Reducing Debt: ELGX's debt to equity ratio has increased from 56.8% to 286.1% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ELGX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ELGX has sufficient cash runway for 2.2 years if free cash flow continues to reduce at historical rates of -6.3% each year.
What is Endologix's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ELGX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate ELGX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ELGX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ELGX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ELGX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Onopchenko (60yo)
Mr. John Onopchenko has been the Chief Executive Officer of Endologix, Inc. since May 2, 2018 and served as its Chief Operating Officer since October 30, 2017 until May 2, 2018. Mr. Onopchenko has been a D ...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD2.20M) is above average for companies of similar size in the US market ($USD626.05K).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
|CEO & Director||1.92yrs||US$2.20m||0.23% $26.9k|
|Chief Financial Officer||4.5yrs||US$1.50m||0.59% $68.7k|
|General Counsel||2.67yrs||US$1.03m||0.043% $5.1k|
|Chief Medical Officer||3.33yrs||US$1.50m||0.086% $10.1k|
|Chief Operations Officer||1.67yrs||no data||no data|
|Chief Technology Officer||4.17yrs||US$927.33k||no data|
|Chief Marketing Officer||2.25yrs||no data||no data|
|Chief Human Resources Officer||1.25yrs||no data||no data|
|Chief Quality Officer||1.83yrs||no data||0.030% $3.5k|
|Chief Commercial Officer||1.25yrs||no data||0.060% $7.1k|
Experienced Management: ELGX's management team is considered experienced (2.1 years average tenure).
|CEO & Director||1.92yrs||US$2.20m||0.23% $26.9k|
|Independent Director||16.42yrs||US$148.50k||0.020% $2.3k|
|Independent Director||9.92yrs||US$134.10k||0.012% $1.4k|
|Independent Director||6.92yrs||US$131.40k||0.052% $6.1k|
|Director||0.083yr||no data||no data|
|Independent Director||4.92yrs||US$135.45k||0.023% $2.7k|
|Independent Chairman||3.17yrs||US$396.60k||0.078% $9.2k|
Experienced Board: ELGX's board of directors are considered experienced (4.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 91.7%.
Endologix, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Endologix, Inc.
- Ticker: ELGX
- Exchange: NasdaqGS
- Founded: 1992
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$11.744m
- Shares outstanding: 19.09m
- Website: https://endologix.com
Number of Employees
- Endologix, Inc.
- 2 Musick
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ELGX||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||May 2002|
|RM11||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||May 2002|
Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which allow physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. It sells its products through direct sales force, and a network of third party distributors and agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/05 23:50|
|End of Day Share Price||2020/04/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.